Lorlatinib

證據等級: L5

預測適應症: 10 個

Lorlatinib: From ALK-Positive NSCLC to Gingival Fibromatosis

One-Sentence Summary

Lorlatinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor established for the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC), as evidenced by the Phase 3 CROWN trial data included in this evidence pack. The TxGNN model's top prediction is Gingival Fibromatosis (a benign fibrous gum overgrowth disorder), with a score of 99.81%, but this prediction is currently supported by zero clinical trials and zero publications — it is a pure embedding-similarity signal with no known mechanistic or clinical basis.

Quick Overview

Item	Content
Original Indication	Not documented in Norway regulatory data (drug not marketed there). Based on attached literature (CROWN Phase 3 RCT, etc.), the established original indication is ALK-positive advanced/metastatic NSCLC
Predicted New Indication	Gingival Fibromatosis
TxGNN Prediction Score	99.81%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for lorlatinib was not available in the structured drug record (original_moa: [Data Gap]). However, based on the attached literature (CROWN trial and related publications), lorlatinib is a brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor with proven efficacy in ALK-positive NSCLC, and broad activity against ALK resistance mutations.

Gingival fibromatosis is a benign, non-neoplastic fibrous overgrowth of gum tissue, most commonly caused by genetic mutations (e.g., SOS1, REST) or connexin-related pathways, or drug-induced (phenytoin, cyclosporine, calcium channel blockers). It has no established relationship to ALK/ROS1 signaling, tyrosine kinase inhibition, or any oncogenic driver pathway targeted by lorlatinib.

The repurposing_rationale attached to this prediction explicitly states there is no known mechanistic link — the drug's rationale field describes this as a pure TxGNN embedding-similarity artifact with "no supporting literature or trials." This means the top-ranked prediction in this evidence pack should be treated as biologically implausible rather than a genuine repurposing signal, and the report below reflects that honestly.

Note on data quality: Several lower-ranked candidates in this evidence pack (ranks 5, 7, 8, 10) have literature attached that appears mismatched to their disease labels — e.g., NSCLC RCT data (CROWN trial) tagged under "lung benign neoplasm," neuroblastoma/glioma case studies tagged under "lung germ cell tumor," frontotemporal dementia reviews tagged under an unrelated genetic syndrome (IBMPFD), and lorlatinib adverse-event case reports tagged under an unrelated dysmorphology syndrome. These appear to be knowledge-graph/ontology node mapping errors and should not be interpreted as clinical support for those specific candidate indications. Only rank 4 (lung hilum carcinoma) shows a plausible mechanistic link, since it is an anatomic-site subtype of ALK+ NSCLC — but is supported by only a single neoadjuvant case report (L4/S1), and arguably represents a restatement of the drug's known indication rather than a novel repurposing target.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

No authorization data available — Lorlatinib is currently not marketed in Norway (total_licenses: 0).

Cytotoxicity (Antineoplastic Drugs Only)

Lorlatinib is classified as antineoplastic based on its established use in NSCLC (per attached literature) and its drug class (ALK/ROS1 tyrosine kinase inhibitor).

Item	Content
Cytotoxicity Classification	Targeted therapy (third-generation ALK/ROS1 tyrosine kinase inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Low. Reported adverse events in the attached literature are predominantly metabolic and neurological rather than hematologic — hypercholesterolemia, hypertriglyceridemia, weight gain, edema, and CNS/mood effects are the hallmark toxicities (per pharmacovigilance and AE-management literature)
Emetogenicity Classification	Low (oral targeted agent; not associated with high emetogenic potential)
Monitoring Items	Fasting lipid panel (cholesterol, triglycerides), weight, CNS/cognitive/mood assessment, blood pressure, liver and renal function; rare reports of nephrotic syndrome and pulmonary toxicity warrant monitoring for proteinuria and respiratory symptoms
Handling Protection	Oral small-molecule kinase inhibitor — standard oral hazardous-drug handling precautions (e.g., per NIOSH hazardous drug list) are appropriate; does not require IV cytotoxic-drug handling protocols

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (Gingival Fibromatosis, 99.81% score) has zero corroborating clinical trials or literature, and the model's own rationale confirms no known mechanistic connection between ALK/ROS1 inhibition and this benign, non-oncologic condition. This is an unsupported L5 (model-only) prediction and does not meet the threshold for further evaluation.

To proceed, the following is needed:

DG001 (Blocking): TFDA/regional drug label warnings and contraindications — required before any S1 safety screening can occur
DG002 (High): Verified MOA data via DrugBank API to properly assess mechanistic plausibility for any future candidate indication
A data-quality review of the TxGNN-to-literature mapping pipeline, given apparent disease-label mismatches identified in ranks 5, 7, 8, and 10 of this evidence pack
If further exploration is warranted, prioritize rank 4 (lung hilum carcinoma) as a research question — it is the only candidate with a plausible mechanistic link and case-level clinical evidence, though it likely falls within the drug's already-approved ALK+ NSCLC indication rather than representing a true new indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.